What Good Are Innovative Technologies for Diabetes Management if People With T1D Can’t Access Them?

: 3 Comments

Together We’re Fighting for Access

When the type 1 community comes together, we’re louder, stronger and more powerful. T1D Exchange is a unique nonprofit that combines our collective voices to demand better treatments and better care. This week, we are highlighting the various ways in which our community has made a difference…Together One.

At T1D Exchange, we recognize the importance of access for people affected by type 1 diabetes, and we’re working hard to raise awareness for the challenges people face in accessing affordable healthcare, treatment and supplies. How? By providing patient-driven evidence to key decision-makers at public payer organizations.

On March 24, 2017, the diabetes community rejoiced at the news that the U.S. Centers for Medicare & Medicaid Services (CMS) had published new criteria for covering the Dexcom G5 Mobile CGM (continuous glucose monitoring) system for all people with diabetes on intensive insulin therapy. This decision came much sooner than expected, but if follows years of hard work, rigorous studies, and advocacy by many stakeholders, including representatives from industry, healthcare, patient advocates and nonprofits like T1D Exchange.

We provided key data that supported the need for CGM in older adult populations as well as the reliability of CGM when making treatment decisions without a finger stick. Two studies, the Replace BG Study and the Hypoglycemia in Older Adults study, as well as feedback from the Glu community, were presented to government regulatory agencies to support Medicare coverage for CGM. You can learn more about this important work here.

Additionally, T1D Exchange research supported increased coverage for test strips in the state of Washington. We conducted a study that proved a strong relationship between the number of times a person with type 1 conducted blood glucose testing and their overall HbA1c levels. This data provided the evidence needed for Washington to increase their coverage from three to 10 strips per day. Without patient data like ours, insurers may not know the real impact of having too few test strips available—increased HbA1c and possible complications—which would likely cost them more in the long run.

As proud as we are of these recent successes, we will not rest. Together, we need to continue to fight for access to those devices and supplies that make such a difference in the overall health of the type 1 community.

To do so, we need your support.

As a 501c3 nonprofit organization, we rely on contributions from people like you to help us continue to accelerate new treatments and improve care. Please consider supporting T1D Exchange research with a donation today.

Sign in or Register to view comments.